SNS Products: Vaccines and Treatment Available for Use in the Mpox Response
ASPR’s Strategic National Stockpile (SNS), in coordination with the Centers for Disease Control and Prevention, is deploying vaccines and treatments to a number of jurisdictions across the United States to support communities affected by mpox.
Vaccines
The SNS holds both JYNNEOS and ACAM2000 vaccines that could be used to protect people from mpox infections. ASPR’s Biomedical Advanced Research and Development Authority (BARDA) supported the development of JYNNEOS, which is approved by the U.S. Food and Drug Administration (FDA) to prevent both smallpox and mpox. ACAM2000®, which was developed with support from SNS, is FDA approved for smallpox but could also be used to vaccinate at-risk individuals under an appropriate regulatory mechanism outside its labeled indication. CDC currently has an expanded access Investigational New Drug protocol that allows its use for mpox.
JYNNEOS vaccine may be shipped either frozen or refrigerated and requires specific cold chain requirements for storage. The requirements for shipment and storage differ from the package insert. Before requesting product, read Bavarian Nordic’s letter on storage requirements for JYNNEOS vaccine and ensure you have a plan to meet these requirements.
Following a
Section 564 determination, the FDA announced an alternate strategy that allows health care providers to draw up to five doses of JYNNEOS vaccine from a single vial when administered intradermally.
Table 1: Lot Numbers and Expiration Dates for SNS-held JYNNEOS vaccine
|
NDC # |
Lot Number(s) |
Expiration |
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00002
FDP00003
FDP00004
FDP00005
|
Aug 31, 2023
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00009
|
May 31, 2024
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00012
|
Aug 31, 2024
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00013
FDP00014
FDP00015
|
Sept 30, 2024
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00016
FDP00017
FDP00018
FDP00019
FDP00020
|
Oct 31, 2024
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00115
|
Jul 31, 2025
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00074
|
Jul 31, 2025
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00117
FDP00118
|
Jul 31, 2025
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00117
FDP00118
|
Jul 31, 2025
|
|
50632-001-01 (vial)
50632-001-02 (20 vials/package)
|
FDP00119
FDP00120
|
Aug 31, 2025
|
Antiviral Drug
The SNS has a supply of the smallpox antiviral drug TPOXX® (tecovirimat), which was developed with BARDA support and can be used to treat individuals with mpox with an appropriate regulatory mechanism. CDC currently has an expanded access Investigational New Drug protocol that allows its use for mpox.
The smallpox antiviral drug TPOXX® supplied by the SNS does not have an expiration date printed on its label. To determine the expiration date for product received from the SNS, find the lot number on the product label, and refer to the table below to identify the corresponding expiration date.
Table 2: Lot Numbers and Expiration Dates for SNS-held oral TPOXX (tecovirimat)
NDC#
|
Lot Number(s) |
Expiration |
|
50072-200-42
|
24601039
24601040
24601041
24601042
24601043
24601044
|
March 2023
|
|
50072-200-42
|
24601045
24601050
|
April 2023
|
|
50072-200-42
|
24601046
24601047
24601048
24601049
24601054
|
May 2023
|
|
50072-200-42
|
24601051
24601052
24601053
|
September 2023
|
|
50072-200-42
|
24601055
24601056
24601057
24601058
|
November 2023
|
|
50072-200-42
|
24601059
24601060
24601063
24601064
|
January 2024
|
|
50072-200-42
|
24601061
24601062
24601065
|
May 2024
|
|
50072-200-42
|
24601066
24601067
24601068
24601069
|
June 2024
|
|
50072-200-42
|
24601073
|
March 2026
|
|
50072-200-42
|
24601075
24601076
24601077
24601078
24601079
24601080
|
February 2027
|
|
50072-200-42
|
24601081
24601082
|
March 2027
|
|
50072-200-42
|
24601092
24601093
24601094
24601095
|
May 2027
|
|
50072-200-42
|
24601096
24601097
24601098
24601099
24601100
24601102
|
April 2028
|
|
50072-200-42
|
24601101
24601103
24601104
24601105
|
May 2028
|
|
50072-200-42
|
24601109
24601110
24601111
24601112
|
December 2028
|
|
50072-200-42
|
24601121
|
February 2029
|
|
50072-200-42
|
24601122
24601123
24601127
|
August 2029
|
|
50072-200-42
|
24601130
24601131
|
January 2030
|
Table 3: Lot Numbers and Expiration Dates for SNS-held intravenous TPOXX (tecovirimat)
NDC#
|
Lot Number(s) |
Expiration |
50072-010-30 |
246V2083
|
31-Jul-2024
|
50072-010-30 |
246V2084
|
30-Nov-2024 |
50072-010-30 |
246V2085
|
28-Feb-2025
|
50072-010-30 |
246V2087
|
31-May-2026
|
50072-010-30 |
246V2088
|
30-Apr-2026
|
50072-010-30 |
246V2089
|
30-Apr-2026
|
50072-010-30 |
246V2090
|
31-May-2026
|
50072-010-30 |
246V2091
|
31-May-2026
|
As of October 26, 2022, the SNS holds Brincidofovir (also known as Tembexa or CMX001). Brincidofovir is an antiviral medication that was
approved by the FDA [PDF – 21 pages] for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
Clinicians with mpox patients necessitating brincidofovir treatment need to submit an e-IND request to FDA by email (DDI.EIND@fda.hhs.gov) or phone 301-796-3400 or 1-855-543-3784 during normal business hours (8 am-4:30 pm ET M-F). During after hours, call the FDA Emergency Coordinator at 1-866-300-4374 or 301-796-8240 or email
CDER-EIND@fda.hhs.gov and call the call the CDER Emergency Coordinator at 301-796-9900.
Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC.
Table 1: Lot Numbers and Expiration Dates for SNS-held Tembexa 100mg tablets
|
NDC # |
Lot Number(s) |
Expiration |
|
79622-010-04 (4 tablets per package)
|
023815
023820
023825
|
Dec 31, 2024
|
|
79622-010-04 (4 tablets per package)
|
024255
024256
024257
|
Aug 31, 2025
|
79622-010-04 (4 tablets per package)
| 022666 | Oct 31, 2025
|
|---|
79622-010-04 (4 tablets per package)
| 022671
| May 31, 2026
|
|---|
Table 2: Lot Numbers and Expiration Dates for SNS-held Tembexa 10mg/ml oral suspension, 65ml
|
NDC # |
Lot Number(s) |
Expiration |
|
79622-012-65 (bottle)
|
0000111036
0000111037
|
Jul 31, 2024
|
|
79622-012-65 (bottle)
|
0000111038
0000111040
|
Aug 31, 2024
|
|
79622-012-65 (bottle)
|
0000111041
|
Mar 31, 2024
|
|
79622-012-65 (bottle)
|
0000127464
|
Jun 30, 2025
|
|
79622-012-65 (bottle)
|
0000127466
|
Jul 31, 2025
|
